Compassionate Use of Remdesivir for Patients with Severe Covid-19.N Engl J Med. 2020 Jun 11; 382(24):2327-2336.NEJM
Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2.
We provided remdesivir on a compassionate-use basis to patients hospitalized with Covid-19, the illness caused by infection with SARS-CoV-2. Patients were those with confirmed SARS-CoV-2 infection who had an oxygen saturation of 94% or less while they were breathing ambient air or who were receiving oxygen support. Patients received a 10-day course of remdesivir, consisting of 200 mg administered intravenously on day 1, followed by 100 mg daily for the remaining 9 days of treatment. This report is based on data from patients who received remdesivir during the period from January 25, 2020, through March 7, 2020, and have clinical data for at least 1 subsequent day.
Of the 61 patients who received at least one dose of remdesivir, data from 8 could not be analyzed (including 7 patients with no post-treatment data and 1 with a dosing error). Of the 53 patients whose data were analyzed, 22 were in the United States, 22 in Europe or Canada, and 9 in Japan. At baseline, 30 patients (57%) were receiving mechanical ventilation and 4 (8%) were receiving extracorporeal membrane oxygenation. During a median follow-up of 18 days, 36 patients (68%) had an improvement in oxygen-support class, including 17 of 30 patients (57%) receiving mechanical ventilation who were extubated. A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation.
In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy. (Funded by Gilead Sciences.).
- Grein J
- Ohmagari N
- Shin D
- Diaz G
- Asperges E
- Castagna A
- Feldt T
- Green G
- Green ML
- Lescure FX
- Nicastri E
- Oda R
- Yo K
- Quiros-Roldan E
- Adenosine Monophosphate
- Administration, Intravenous
- Aged, 80 and over
- Antiviral Agents
- Compassionate Use Trials
- Coronavirus Infections
- Middle Aged
- Pneumonia, Viral
- Respiration, Artificial
- United States
- Young Adult
- COVID-19 Drug Treatment
- Remdesivir for the Treatment of Covid-19 - Final Report.
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
- Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status.
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
- Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
- Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019.
- Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU.
- Have we found the panacea to COVID-19 with remdesivir, an old but newly packaged drug?
- Compassionate Use of Remdesivir in Children With Severe COVID-19.
- Case report study of the first five COVID-19 patients treated with remdesivir in France.